Ítem
Solo Metadatos
Using PICO Methodology to Answer Questions About Smoking in COPD Patients
Título de la revista
Autores
Jiménez Ruiz C.A.
Buljubasich D.
Riesco Miranda J.A.
Acuña Izcaray A.
de Granda Orive J.I.
Chatkin J.M.
Zabert G.
Guerreros Benavides A.
Paez Espinel N.
Noé V.
Fecha
2017
Directores
ISSN de la revista
Título del volumen
Editor
Elsevier Doyma
Buscar en:
Métricas alternativas
Resumen
Abstract
The ALAT and SEPAR Treatment and Control of Smoking Groups have collaborated in the preparation of this document which attempts to answer, by way of PICO methodology, different questions on health interventions for helping COPD patients to stop smoking. The main recommendations are: (i) moderate-quality evidence and strong recommendation for performing spirometry in COPD patients and in smokers with a high risk of developing the disease, as a motivational tool (particularly for showing evidence of lung age), a diagnostic tool, and for active case-finding; (ii) high-quality evidence and strong recommendation for using intensive dedicated behavioral counselling and drug treatment for helping COPD patients to stop smoking; (iii) high-quality evidence and strong recommendation for initiating interventions for helping COPD patients to stop smoking during hospitalization with improvement when the intervention is prolonged after discharge, and (iv) high-quality evidence and strong recommendation for funding treatment of smoking in COPD patients, in view of the impact on health and health economics. © 2017 SEPAR
Palabras clave
Keywords
Article , Chronic obstructive lung disease , Counseling , High risk patient , Hospital discharge , Hospitalization , Human , Smoking , Smoking cessation , Spirometry , Age , Health economics , High risk population , Smoking habit , Chronic obstructive lung disease , Clinical trial (topic) , Cost benefit analysis , Drug therapy , Economics , Evidence based medicine , Motivation , Pathophysiology , Procedures , Psychology , Questionnaire , Randomized controlled trial (topic) , Smoking , Therapy , Amfebutamone , Biological marker , Nicotine , Nicotinic agent , Varenicline , Biomarkers , Bupropion , Clinical Trials as Topic , Cost-Benefit Analysis , Counseling , Evidence-Based Medicine , Humans , Motivation , Nicotine , Nicotinic Agonists , Pulmonary Disease , Randomized Controlled Trials as Topic , Smoking , Smoking Cessation , Spirometry , Surveys and Questionnaires , Varenicline , Chronic obstructive pulmonary disease , Smoking , Spirometry , Treatment
